Flexion Therapeutics Inc (FLXN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Flexion Therapeutics Inc (FLXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014064
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Flexion Therapeutics Inc (Flexion) is a pharmaceutical company that develops and commercializes pain therapies. The company’s products comprise FX006, FX007, and FX005. Its FX005 is a p38 mitogen-activated protein, kinase inhibitor that contains both analgesic and anti-inflammatory properties. It provides FX006, an injectable, intra-articular, sustained release drug to provide long lasting, local analgesia. The company offers FX007, a preclinical, small molecule TrkA receptor antagonist designed to treat post-operative pain. It offers anti-inflammatory and analgesic therapies for osteoarthritis. Flexion is headquartered in Burlington, Massachusetts, the US.

Flexion Therapeutics Inc (FLXN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Flexion Therapeutics Raises US$20 Million In Series B Financing 10
Flexion Therapeutics Raises Additional US$13 Million In Series A Financing 12
Licensing Agreements 13
Flexion Therapeutics Enters into Licensing Agreement with Southwest Research Institute 13
Equity Offering 14
Flexion Therapeutics Prices Public Offering of Shares for USD122.4 Million 14
Flexion Therapeutics Raises USD74.5 Million in Public Offering of Shares 16
Flexion Therapeutics Raises USD82.6 Million in Public Offering of Shares 18
Flexion Therapeutics Raises USD98.5 Million in Public Offering of Shares 20
Flexion Therapeutics Completes IPO For US$74.7 Million 22
Debt Offering 24
Flexion Therapeutics Raises USD201.3 Million in Private Placement of 3.375% Notes Due 2024 24
Acquisition 25
Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 25
Flexion Therapeutics Inc – Key Competitors 26
Flexion Therapeutics Inc – Key Employees 27
Flexion Therapeutics Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Nov 06, 2017: Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights 29
Aug 08, 2017: Flexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights 30
May 04, 2017: Flexion Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights 31
Mar 09, 2017: Flexion Reports Year-End 2016 Financial Results 32
Nov 07, 2016: Flexion Therapeutics Reports Third Quarter 2016 Financial Results 33
Aug 03, 2016: Flexion Therapeutics Reports Second-Quarter 2016 Financial Results 34
May 12, 2016: Flexion Therapeutics Reports First-Quarter 2016 Financial Results 35
Mar 10, 2016: Flexion Reports Year-End 2015 Financial Results 36
Corporate Communications 37
Jun 28, 2017: Flexion Therapeutics appoints new senior vice president, general counsel and secretary 37
Apr 07, 2017: Flexion Therapeutics Announces Appointment of Yamo Deniz, MD, as Chief Medical Officer 38
Sep 14, 2016: Flexion Therapeutics Announces Appointment of Mark Stejbach to its Board of Directors 39
Product News 40
07/10/2017: Flexion Therapeutics: Update on FX101 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Flexion Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Flexion Therapeutics Raises US$20 Million In Series B Financing 10
Flexion Therapeutics Raises Additional US$13 Million In Series A Financing 12
Flexion Therapeutics Enters into Licensing Agreement with Southwest Research Institute 13
Flexion Therapeutics Prices Public Offering of Shares for USD122.4 Million 14
Flexion Therapeutics Raises USD74.5 Million in Public Offering of Shares 16
Flexion Therapeutics Raises USD82.6 Million in Public Offering of Shares 18
Flexion Therapeutics Raises USD98.5 Million in Public Offering of Shares 20
Flexion Therapeutics Completes IPO For US$74.7 Million 22
Flexion Therapeutics Raises USD201.3 Million in Private Placement of 3.375% Notes Due 2024 24
Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 25
Flexion Therapeutics Inc, Key Competitors 26
Flexion Therapeutics Inc, Key Employees 27

★海外企業調査レポート[Flexion Therapeutics Inc (FLXN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Henry Schein, Inc.:企業のM&A・事業提携・投資動向
    Henry Schein, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Henry Schein, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Al-Nisr Al Arabi Insurance Company:企業の戦略・SWOT・財務情報
    Al-Nisr Al Arabi Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Al-Nisr Al Arabi Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773):製薬・医療:M&Aディール及び事業提携情報
    Summary Chengdu Kanghong Pharmaceuticals Group Co Ltd (Chengdu Kanghong Pharmaceuticals) is a pharmaceutical company that develops, manufactures and markets Chinese medicines, chemical drugs and biological products. The company offers products for the treatment of medical conditions related to centr …
  • Genentech Inc:医療機器:M&Aディール及び事業提携情報
    Summary Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including bio-oncology, immunology, ophthalmology …
  • BOC Aviation Limited (2588):企業の財務・戦略的SWOT分析
    BOC Aviation Limited (2588) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Argan Inc (AGX):企業の財務・戦略的SWOT分析
    Argan Inc (AGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Tarsa Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Tarsa Therapeutics Inc (Tarsa) develops therapies for the treatment and prevention of osteoporosis and other bone related diseases. The company develops TBRIA, an oral formulation of calcitonin, a peptide hormone that inhibits bone resorption, which is used for the treatment of postmenopausa …
  • AcelRx Pharmaceuticals Inc (ACRX):医療機器:M&Aディール及び事業提携情報
    Summary AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo outside the US), is a single sufentanil sublingual tablet for the treatment of moderate-t …
  • Clicks Group Limited:企業の戦略・SWOT・財務分析
    Clicks Group Limited - Strategy, SWOT and Corporate Finance Report Summary Clicks Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sistema JSFC:企業の戦略・SWOT・財務分析
    Sistema JSFC - Strategy, SWOT and Corporate Finance Report Summary Sistema JSFC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • MAN Energy Solutions SE:企業の戦略的SWOT分析
    MAN Energy Solutions SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • First Solar, Inc.:企業の戦略・SWOT・財務情報
    First Solar, Inc. - Strategy, SWOT and Corporate Finance Report Summary First Solar, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Bioasis Technologies Inc (BTI):企業の財務・戦略的SWOT分析
    Summary Bioasis Technologies Inc (BTI) operates as a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents …
  • Even Construtora E Incorporadora Sa
    Even Construtora E Incorporadora Sa - Strategy, SWOT and Corporate Finance Report Summary Even Construtora E Incorporadora Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • PhoenixBio Co Ltd (6190):企業の財務・戦略的SWOT分析
    Summary PhoenixBio Co Ltd (PhoenixBio) is a life science company that offers medical therapy solutions. The company offers contract study services including dosing of test-compounds, sampling, chemical analysis, in-life phase trials, measurement of human albumin levels, and metabolic enzymes and blo …
  • Trilliant Holdings, Inc.:企業の戦略的SWOT分析
    Trilliant Holdings, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Country Road Group Pty Ltd:企業の戦略的SWOT分析
    Country Road Group Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Chiltern International Inc-製薬・医療分野:企業M&A・提携分析
    Summary Chiltern International Inc (Chiltern) is a contract research organization that provides clinical trial development services. It conducts clinical trials for medical devices, drugs, and diagnostics across all stages of development. The company offer wide range of services including clinical d …
  • Catalent Inc:企業の戦略・SWOT・財務情報
    Catalent Inc - Strategy, SWOT and Corporate Finance Report Summary Catalent Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Entravision Communications Corporation (EVC):企業の財務・戦略的SWOT分析
    Entravision Communications Corporation (EVC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆